Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa

San Francisco, USA; Toronto, Canada; Zürich, Switzerland, April 5, 2023 Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous regenerative medicines, announced today that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed. No clinically relevant or dose-limiting adverse events were identified after […]

Daniel Froehlich becomes Head of Finance at Endogena Therapeutics

Zürich, Switzerland – January 2023 After a long career in different areas of finance and controlling for stock market-listed Swiss multinational groups, SMEs, in different industries, such as medical technology, Daniel decided to join the start-up, biotech pharmaceutical industry. His extensive experience as a CFO and COO will be crucial for our growing company. “We […]

Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa

San Francisco, USA; Toronto, Canada; Zürich, Switzerland, February 6, 2023 Endogena Therapeutics Inc., a clinical-stage biotech company focused on thedevelopment of endogenous regenerative medicines, announced today that the USFood and Drug Administration (FDA) has designated the investigation of EA-2353 forthe treatment of retinitis pigmentosa (RP) as a Fast Track developmentprogram. Fast Track is a process […]

Sven Weiler joins Endogena as VP Medicinal Chemistry

We are pleased to announce that Sven Weiler has joined our team in Schlieren, Switzerland as Vice President Medicinal Chemistry on August 1st, 2022. “I very much look forward to becoming an integral part of Endogena Therapeutics and to extend my expertise among this passionate group of colleagues. It’s exciting to be joining a company […]

Endogena receives Retina Innovation Award at event showcasing new therapies for eye conditions

July 13th, New York, NY Poignantly crafted from the clearest crystal, the Retina Innovation Award that now claims pride of place in Endogena Therapeutics’ trophy cabinet represents how far the company has come in developing a potential new treatment for people losing their sight because of retinitis pigmenosa (RP).  More than 350 international delegates including clinicians, […]

Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa

Zürich, Switzerland and Toronto, Canada; 12th July 2022 Endogena Therapeutics Inc. announced today that the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of […]

Michael Lai joins Endogena as Medical Director 

As Endogena Therapeutics is moving into the next phase from a pre-clinical to a clinical stage company, we are pleased to announce that Michael Lai has joined our team as Medical Director Clinical Development on April 1st, 2022.   “We are excited to kick-off this critical stage in our company’s development with such a high-profile candidate […]